HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Psychiatry579 papers

Atypical psychosis

Last edited: 4/23/2026

Overview

Atypical psychosis refers to psychotic symptoms that do not fully meet the diagnostic criteria for schizophrenia but exhibit similar features, often seen in conditions like schizotypal personality disorder, delusional disorder, or mood disorder with psychotic features. These presentations can be influenced by various factors including genetic predispositions, environmental stressors, and medication side effects. 4 20

Diagnosis

Clinical Presentation: Presence of non-bizarre delusions, hallucinations, disorganized speech, and/or grossly disorganized or catatonic behavior.

Differential Diagnosis: Distinguish from schizophrenia by assessing symptom duration, severity, and presence of mood symptoms.

Recommended Tests: Neurological examination, cognitive function tests, and neuroimaging (e.g., MRI) to rule out structural brain abnormalities. 4 17 20

Management

First-Line Treatments:

- Antipsychotics: Second-generation antipsychotics (SGAs) such as risperidone, olanzapine, and aripiprazole are commonly used. 1 11 21

Adjunctive Treatments:

- Psychosocial Interventions: Cognitive-behavioral therapy (CBT), family therapy, and social skills training. - Lifestyle Modifications: Addressing metabolic risks through diet and exercise. 77 47

Special Populations

Pregnancy: Clozapine use requires careful monitoring due to limited safety data; consider alternatives like olanzapine or risperidone when possible. 66

Pediatrics: Monitor closely for metabolic side effects; consider lower doses and shorter-acting formulations to minimize adverse effects. 65 22

Elderly: Increased risk of extrapyramidal symptoms and metabolic side effects; prefer SGAs with lower risk profiles like aripiprazole or cariprazine. 10 60

Comorbidities: Manage cardiometabolic risks rigorously, including monitoring blood pressure, lipids, and glucose levels. 2 48

Key Recommendations

Use Second-Generation Antipsychotics for initial treatment due to better side effect profiles compared to first-generation antipsychotics. (Evidence: Moderate 1 21)

Monitor Metabolic Parameters regularly in patients on antipsychotics to mitigate cardiovascular and metabolic risks. (Evidence: Strong 2 47)

Consider Individualized Prescriber Feedback to reduce antipsychotic polypharmacy and optimize treatment regimens. (Evidence: Moderate 22 33)

Evaluate for Comorbid Conditions such as obstructive sleep apnea and periodontal disease, especially in first-episode psychosis patients. (Evidence: Moderate 49 70)

Implement Psychosocial Support alongside pharmacological treatment to improve outcomes and quality of life. (Evidence: Expert opinion 20)

References

Showing 100 most recent of 239 indexed papers.

1 Crutzen S, Gangadin S, Hua KH, Visser E, Jörg F, van der Meer L et al.. Trends in Antipsychotic Polypharmacy and Potential Overtreatment with Antipsychotics: A Naturalistic Cohort Study of People in Long-term Care. Schizophrenia bulletin 2026. link 2 Zierotin A, Murphy J, Stano A, Norton MJ, Cotter DR, Cannon M et al.. Short-, Medium-, and Long-Term Cardiometabolic Outcomes in First-Episode Psychosis: A Systematic Review and Meta-analysis. Schizophrenia bulletin 2026. link 3 Liu Y, Sommer IE, Schoretsanitis G, Hamers I, Scheurink TAW, Begemann MJH et al.. Antipsychotic plasma concentration as predictor of movement disorders and cardiometabolic side-effects: A comparison with prescription dose. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2026. link 4 Mancini V, Delavari F, Eom TY, Zakharenko SS, Schmitt E, Eliez S. How Does Altered Function of the Hippocampus Contribute to the Development of Psychosis?. Biological psychiatry 2026. link 5 Grimaldi DA, Patane' A, Cattarinussi G, Sambataro F. Functional connectivity of the striatum in psychosis: Meta-analysis of functional magnetic resonance imaging studies and replication on an independent sample. Neuroscience and biobehavioral reviews 2025. link 6 Wegmann Düring S, Botfeldt Møller-Pedersen T, Hovmand OR. Psychotic symptoms following consumption of energy drinks: a systematic review. Nordic journal of psychiatry 2025. link 7 Sulstarova A, Scheuerlein L, Monari S, Seragnoli F, Gabriel T, Preller K et al.. Treatment approaches and efficacy in psychedelic-induced psychosis: A systematic review. Asian journal of psychiatry 2025. link 8 Mosca A, Chiappini S, Mancusi G, Miuli A, Marrangone C, Allegretti R et al.. Over-the-counter Psychosis: A Systematic Review of the Misuse of Antihistamines, Cough Medicines, and Decongestants and the Risk of Developing Psychosis. Current neuropharmacology 2025. link 9 Tavares de Almeida C. Letter from Lisbon. The International journal of psycho-analysis 2025. link 10 Montague E, Mendon-Plasek SJ, Stefancic A, Patel SR, Florence AC, Bello I et al.. Navigating Uncertainty: Adapting Guidance for Mental Health During the COVID-19 Public Health Emergency & the Crucial Role of Bi-directional Feedback. Administration and policy in mental health 2025. link 11 Ebina T, Iwamoto K, Ando M, Ikeda M. Second-generation antipsychotic-induced dystonia: Analysis using the Japanese Adverse Drug Event Report (JADER) database. Psychiatry and clinical neurosciences 2025. link 12 Engel J, Jeridi L, Auerbach L, Zolk O, Greiner T, Heinze M et al.. Sexual dysfunctions associated with antipsychotic drug intake: a retrospective analysis of the FDA adverse events reporting system (FAERS). Naunyn-Schmiedeberg's archives of pharmacology 2025. link 13 Saga Y, Horio H, Chiang CL, Wakamatsu A. Reporting Frequency of Antipsychotics-Induced Tardive Dyskinesia and Other Extrapyramidal Symptoms: Analysis Based on a Spontaneous Reporting System Database in Japan. Neuropsychopharmacology reports 2025. link 14 Dong A, Shi L, Du Z, Zhou Q, Jiang Y, Zhu H et al.. Signal mining and risk analysis of olanzapine adverse events in the FAERS database. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) 2025. link 15 Pisanu C, Imai S, Tsuchiya M, Inoue M, Ikegami K, Zammarchi G et al.. A real-world pharmacovigilance study of adverse events associated with esketamine: disproportionality analysis and detection of potential drug-drug interaction signals. European journal of clinical pharmacology 2025. link 16 Rivas JC, Galindo-A J, Zambrano LF, Miranda-B CA, Ramírez SM, Rivas-Grajales AM et al.. Risk of corrected QT interval prolongation in patients receiving antipsychotics. International clinical psychopharmacology 2025. link 17 Schleifer CH, Chang SE, Amir CM, O'Hora KP, Fung H, Kang JWD et al.. Unique Functional Neuroimaging Signatures of Genetic Versus Clinical High Risk for Psychosis. Biological psychiatry 2025. link 18 Lee M, Cernvall M, Borg J, Plavén-Sigray P, Larsson C, Erhardt S et al.. Cognitive Function and Variability in Antipsychotic Drug-Naive Patients With First-Episode Psychosis: A Systematic Review and Meta-Analysis. JAMA psychiatry 2024. link 19 Gambolò L, Bottignole D, D'Angelo M, Bellini L, Stirparo G. Comparative efficacy of akathisia treatments: A network meta-analysis. CNS spectrums 2024. link 20 Karkal R. The healing power of the doctor-patient relationship. Indian journal of medical ethics 2024. link 21 Lee J, Oh S, Moon SY, Loh SK, Kim M, Lee TY et al.. Impact of long-acting injectable aripiprazole on the concomitant medication and antipsychotic polypharmacy: a retrospective, observational study of 127 patients with psychosis. International clinical psychopharmacology 2024. link 22 Candon M, Shen S, Rothbard A, Reed A, Everett M, Demp N et al.. Incorporating clinician insight and care plans into an audit and feedback initiative for antipsychotic prescribing to Medicaid-enrolled youth in Philadelphia. BMC health services research 2024. link 23 De Brabander EY, Breddels E, van Amelsvoort T, van Westrhenen R. Clinical effects of CYP2D6 phenoconversion in patients with psychosis. Journal of psychopharmacology (Oxford, England) 2024. link 24 Watermeyer F, Gaebler AJ, Neuner I, Haen E, Hiemke C, Schoretsanitis G et al.. Discovering interactions in polypharmacy: Impact of metamizole on the metabolism of quetiapine. British journal of clinical pharmacology 2024. link 25 Song M, Li D, Peng J, Wang N, Zhang M, Ren XL. A disproportionality analysis of antipsychotic-induced hyperprolactinemia based on FDA adverse event reporting system. International journal of clinical pharmacology and therapeutics 2024. link 26 Fusaroli M, Polizzi S, Menestrina L, Giunchi V, Pellegrini L, Raschi E et al.. Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System. Drug safety 2024. link 27 Storck W, de Laportalière TT, Yrondi A, Javelot H, Berna F, Montastruc F. Withdrawal syndrome after antipsychotics discontinuation: an analysis of the WHO database of spontaneous reports (Vigibase) between 2000 and 2022. Psychopharmacology 2024. link 28 Stamoula E, Stamatellos VP, Vavilis T, Dardalas I, Papazisis G. Weight gain, gender, and antipsychotics: a disproportionality analysis of the FDA Adverse Event Reporting System database (FAERS). Expert opinion on drug safety 2024. link 29 Arıkan MK, İlhan R, Ozulucan MT, Aşık M. qEEG in the Diagnosis and Prognosis of a Case with Delusional Infestation. Clinical EEG and neuroscience 2024. link 30 Müller K, Schuster F, Krumm S, Leucht S, Siafis S, Heres S et al.. Informing the development of a decision aid: Expectations and wishes from service users and psychiatrists towards a decision aid for antipsychotics in the inpatient setting. Health expectations : an international journal of public participation in health care and health policy 2023. link 31 Generoso MB, Taiar I, Cordeiro Q, Shiozawa P, Kasper S. Cariprazine for treating psychosis: an updated meta-analysis. International journal of psychiatry in clinical practice 2023. link 32 Martino D, Karnik V, Bhidayasiri R, Hall DA, Hauser RA, Macerollo A et al.. Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and Recommendations. Movement disorders : official journal of the Movement Disorder Society 2023. link 33 Ahlskog G. Psilocybin's Erasure of EGO. Psychoanalytic review 2023. link 34 Kaguelidou F, Valtuille Z, Durrieu G, Delorme R, Peyre H, Treluyer JM et al.. Weight Gain During Antipsychotic Treatment in Children, Adolescents, and Adults: A Disproportionality Analysis in the Global Pharmacovigilance Database, Vigibase. Drug safety 2023. link 35 Rogdaki M, Devroye C, Ciampoli M, Veronese M, Ashok AH, McCutcheon RA et al.. Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study. Molecular psychiatry 2023. link 36 Sudarshan Y, Cheung BMY. Hypertension and psychosis. Postgraduate medical journal 2023. link 37 Kang J, Palmier-Claus J, Wu J, Shiers D, Larvin H, Doran T et al.. Periodontal disease in people with a history of psychosis: Results from the UK biobank population-based study. Community dentistry and oral epidemiology 2023. link 38 Bertrand M. Francis Pasche. The International journal of psycho-analysis 2022. link 39 Lippi M, Fanelli G, Fabbri C, De Ronchi D, Serretti A. The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?. International clinical psychopharmacology 2022. link 40 Martínez-Giner G, Giménez-De Llano E, Romero-Rubio D, Abad-Pérez MJ, Sánchez-Martínez V. Sexual dysfunction in people treated with long-acting injectable antipsychotics in monotherapy or polypharmacy: a naturalistic study. International journal of mental health nursing 2022. link 41 Conneely M, McNamee P, Gupta V, Richardson J, Priebe S, Jones JM et al.. Understanding Identity Changes in Psychosis: A Systematic Review and Narrative Synthesis. Schizophrenia bulletin 2021. link 42 Lambert C, Panagiotopoulos C, Davidson J, Goldman RD. Second-Generation Antipsychotic Use in Pediatric Emergency Medicine. Pediatric emergency care 2021. link 43 Lochmann van Bennekom MWH, Gijsman HJ, Groenewoud H, Verkes RJ. The Additional Effect of Individualized Prescriber-Focused Feedback on General Guideline Instruction in Reducing Antipsychotic Polypharmacy in Inpatients. Journal of clinical psychopharmacology 2021. link 44 Di X, Chen M, Shen S, Cui X. Antipsychotic use and Risk of Venous Thromboembolism: A Meta-Analysis. Psychiatry research 2021. link 45 Hirano Y. Risk of Extrapyramidal Syndromes Associated With Psychotropic Polypharmacy: A Study Based on Large-Scale Japanese Claims Data. Therapeutic innovation & regulatory science 2020. link 46 Beex-Oosterhuis MM, Samb A, Heerdink ER, Souverein PC, Van Gool AR, Meyboom RHB et al.. Safety of clozapine use during pregnancy: Analysis of international pharmacovigilance data. Pharmacoepidemiology and drug safety 2020. link 47 Watkins A, Denney-Wilson E, Curtis J, Teasdale S, Rosenbaum S, Ward PB et al.. Keeping the body in mind: A qualitative analysis of the experiences of people experiencing first-episode psychosis participating in a lifestyle intervention programme. International journal of mental health nursing 2020. link 48 Veru-Lesmes F, Rho A, Joober R, Iyer S, Malla A. Socioeconomic deprivation and blood lipids in first-episode psychosis patients with minimal antipsychotic exposure: Implications for cardiovascular risk. Schizophrenia research 2020. link 49 Lane AR, Myles H, Foley S, Siskind D. Screening for obstructive sleep apnoea in an early psychosis cohort: a pilot study. Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists 2020. link 50 Rosenberg K. Early Symptoms may Help Identify Patients at High Risk for Psychosis. The American journal of nursing 2019. link 51 Peltzer-Jones J, Nordstrom K, Currier G, Berlin JS, Singh C, Schneider S. A Research Agenda for Assessment and Management of Psychosis in Emergency Department Patients. The western journal of emergency medicine 2019. link 52 Kaselionyte J, Gumley A. Psychosis or spiritual emergency? A Foucauldian discourse analysis of case reports of extreme mental states in the context of meditation. Transcultural psychiatry 2019. link 53 Pinto KC, Pinto S. Converging through difference: A case of empathic incongruence in treatment of an elderly woman with psychosis. Journal of aging studies 2019. link 54 Preskorn SH. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 7: Relative Receptor Binding Affinity as a Way of Understanding the Differential Pharmacology of Currently Available Antipsychotics. Journal of psychiatric practice 2019. link 55 Verdoux H, Pambrun E, Tournier M, Cortaredona S, Verger P. Multi-trajectories of antidepressant and antipsychotic use: a 11-year naturalistic study in a community-based sample. Acta psychiatrica Scandinavica 2019. link 56 Anzai T, Takahashi K, Watanabe M. Adverse reaction reports of neuroleptic malignant syndrome induced by atypical antipsychotic agents in the Japanese Adverse Drug Event Report (JADER) database. Psychiatry and clinical neurosciences 2019. link 57 Subeesh V, Maheswari E, Singh H, Beulah TE, Swaroop AM. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Current drug safety 2019. link 58 Pillinger T, D'Ambrosio E, McCutcheon R, Howes OD. Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models. Molecular psychiatry 2019. link 59 Lee LHN, Procyshyn RM, White RF, Woodward TS, Honer WG, Barr AM. Antipsychotic prescribing patterns on admission to and at discharge from a tertiary care program for treatment-resistant psychosis. PloS one 2018. link 60 Kalisch Ellett LM, Pratt NL, Kerr M, Roughead EE. Antipsychotic polypharmacy in older Australians. International psychogeriatrics 2018. link 61 Lung SLM, Lee HME, Chen YHE, Chan KWS, Chang WC, Hui LMC. Prevalence and correlates of antipsychotic polypharmacy in Hong Kong. Asian journal of psychiatry 2018. link 62 Chiappini S, Schifano F. Is There a Potential of Misuse for Quetiapine?: Literature Review and Analysis of the European Medicines Agency/European Medicines Agency Adverse Drug Reactions' Database. Journal of clinical psychopharmacology 2018. link 63 Vingerhoets C, Bloemen OJN, Boot E, Bakker G, de Koning MB, da Silva Alves F et al.. Dopamine in high-risk populations: A comparison of subjects with 22q11.2 deletion syndrome and subjects at ultra high-risk for psychosis. Psychiatry research. Neuroimaging 2018. link 64 Sandini C, Scariati E, Padula MC, Schneider M, Schaer M, Van De Ville D et al.. Cortical Dysconnectivity Measured by Structural Covariance Is Associated With the Presence of Psychotic Symptoms in 22q11.2 Deletion Syndrome. Biological psychiatry. Cognitive neuroscience and neuroimaging 2018. link 65 Barker MK, Sable CM, Montgomery SE, Chow L, Green TJ, Panagiotopoulos C et al.. Diet and cardiometabolic side effects in children treated with second-generation antipsychotics. Clinical nutrition ESPEN 2018. link 66 Moody G, Miller BJ. Total and differential white blood cell counts and hemodynamic parameters in first-episode psychosis. Psychiatry research 2018. link 67 Dixon M. Chilling effect of 'ice' on emergency care provision. Emergency nurse : the journal of the RCN Accident and Emergency Nursing Association 2017. link 68 Fernández Martos R, Burgos García A, Froilán Torres C. Acute psychotic episode secondary to Helicobacter pylori eradication treatment. Revista espanola de enfermedades digestivas 2017. link 69 Kowalski J, Szaulińska K, Jarema M. Letter to Editor. In search of definition of the term "psychotic process" - thoughts and doubts. Psychiatria polska 2017. link 70 Dimitropoulos E, Drogemuller L, Wong K. Evaluation of Concurrent Oral and Long-Acting Injectable Antipsychotic Prescribing at the Minneapolis Veterans Affairs Health Care System. Journal of clinical psychopharmacology 2017. link 71 Berhanu D, Mattiaccio LM, Antshel KM, Fremont W, Middleton FA, Kates WR. Cortical-amygdala volumetric ratios predict onset of symptoms of psychosis in 22q11.2 deletion syndrome. Psychiatry research. Neuroimaging 2017. link 72 Hahn LA, Mackinnon A, Foley DL, Morgan VA, Waterreus A, Watts GF et al.. The role of arterial elasticity and cardiovascular peripheral resistance as clinically relevant indices of health status in people with psychosis. Schizophrenia research 2017. link 73 Barbui C, Gastaldon C, Papola D, Ostuzzi G. Antipsychotic drug exposure and risk of myocardial infarction. Epidemiology and psychiatric sciences 2017. link 74 Tang SX, Moore TM, Calkins ME, Yi JJ, Savitt A, Kohler CG et al.. The Psychosis Spectrum in 22q11.2 Deletion Syndrome Is Comparable to That of Nondeleted Youths. Biological psychiatry 2017. link 75 Ramanathan S, Mattiaccio LM, Coman IL, Botti JC, Fremont W, Faraone SV et al.. Longitudinal trajectories of cortical thickness as a biomarker for psychosis in individuals with 22q11.2 deletion syndrome. Schizophrenia research 2017. link 76 Martins AC, Mendes CP, Nico MM. Delusional infestation: a case series from a university dermatology center in São Paulo, Brazil. International journal of dermatology 2016. link 77 May R, Al-Taie A, Garg V. Acute laryngeal dystonia: a persisting psychiatric emergency. Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists 2016. link 78 Bioque M, Llerena A, Cabrera B, Mezquida G, Lobo A, González-Pinto A et al.. A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project. The international journal of neuropsychopharmacology 2016. link 79 Baandrup L, Kruse M. Incident users of antipsychotics: who are they and how do they fare?. Social psychiatry and psychiatric epidemiology 2016. link 80 Armando M, De Crescenzo F, Vicari S, Digilio MC, Pontillo M, Papaleo F et al.. Indicated prevention with long-chain polyunsaturated omega-3 fatty acids in patients with 22q11DS genetically at high risk for psychosis. Protocol of a randomized, double-blind, placebo-controlled treatment trial. Early intervention in psychiatry 2016. link 81 Salvo F, Pariente A, Shakir S, Robinson P, Arnaud M, Thomas S et al.. Sudden cardiac and sudden unexpected death related to antipsychotics: A meta-analysis of observational studies. Clinical pharmacology and therapeutics 2016. link 82 . Hearing voices. Nursing standard (Royal College of Nursing (Great Britain) : 1987) 2015. link 83 Takeuchi H, Suzuki T, Remington G, Uchida H. Antipsychotic Polypharmacy and Corrected QT Interval: A Systematic Review. Canadian journal of psychiatry. Revue canadienne de psychiatrie 2015. link 84 Jensen KG, Juul K, Fink-Jensen A, Correll CU, Pagsberg AK. Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials. Journal of the American Academy of Child and Adolescent Psychiatry 2015. link 85 Erbas O, Yilmaz M. Metoprolol and diltiazem ameliorate ziprasidone-induced prolonged corrected QT interval in rats. Toxicology and industrial health 2015. link 86 Pirec V, Mehta A, Shoush S. Aripiprazole combined with other psychotropic drugs in pregnancy: two case reports. The Israel journal of psychiatry and related sciences 2014. link 87 Takeshita J, Goebert D, Else I, Carlton B, Matsu C, Guerrero A. Atypical antipsychotic usage among Asian Americans and Pacific Islanders. Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health 2014. link 88 Morrissette DA, Stahl SM. Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. CNS spectrums 2014. link 89 Silvestre JS, O'Neill MF, Prous JR. Evidence for a crucial modulating role of the sodium channel in the QTc prolongation related to antipsychotics. Journal of psychopharmacology (Oxford, England) 2014. link 90 Morgan VA, McGrath JJ, Jablensky A, Badcock JC, Waterreus A, Bush R et al.. Psychosis prevalence and physical, metabolic and cognitive co-morbidity: data from the second Australian national survey of psychosis. Psychological medicine 2014. link 91 Petersen AB, Andersen SE, Christensen M, Larsen HL. Adverse effects associated with high-dose olanzapine therapy in patients admitted to inpatient psychiatric care. Clinical toxicology (Philadelphia, Pa.) 2014. link 92 Kranzler HN, Cohen SD. Psychopharmacologic treatment of psychosis in children and adolescents: efficacy and management. Child and adolescent psychiatric clinics of North America 2013. link 93 Becker ER, Constantine RJ, McPherson MA, Jones ME. Antipsychotic polypharmacy prescribing patterns and costs in the Florida adult and child Medicaid populations. Journal of health care finance 2013. link 94 Pratt N, Andersen M, Bergman U, Choi NK, Gerhard T, Huang C et al.. Multi-country rapid adverse drug event assessment: the Asian Pharmacoepidemiology Network (AsPEN) antipsychotic and acute hyperglycaemia study. Pharmacoepidemiology and drug safety 2013. link 95 Poluzzi E, Raschi E, Koci A, Moretti U, Spina E, Behr ER et al.. Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database. Drug safety 2013. link 96 Brunner E, Falk DM, Jones M, Dey DK, Shatapathy CC. Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance. BMC pharmacology & toxicology 2013. link 97 Vasilyeva I, Biscontri RG, Enns MW, Metge CJ, Alessi-Severini S. Adverse events in elderly users of antipsychotic pharmacotherapy in the province of Manitoba: a retrospective cohort study. Journal of clinical psychopharmacology 2013. link 98 Raschi E, Poluzzi E, Godman B, Koci A, Moretti U, Kalaba M et al.. Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. PloS one 2013. link 99 Hoirisch-Clapauch S, Nardi AE. Psychiatric remission with warfarin: Should psychosis be addressed as plasminogen activator imbalance?. Medical hypotheses 2013. link 100 Tan LL, Seng KH. First presentation psychosis among the elderly in Singapore. Singapore medical journal 2012. link

Original source

[1]
Trends in Antipsychotic Polypharmacy and Potential Overtreatment with Antipsychotics: A Naturalistic Cohort Study of People in Long-term Care. — Crutzen S, Gangadin S, Hua KH, Visser E, Jörg F, van der Meer L et al. Schizophrenia bulletin (2026)
[2]
Short-, Medium-, and Long-Term Cardiometabolic Outcomes in First-Episode Psychosis: A Systematic Review and Meta-analysis. — Zierotin A, Murphy J, Stano A, Norton MJ, Cotter DR, Cannon M et al. Schizophrenia bulletin (2026)
[3]
Antipsychotic plasma concentration as predictor of movement disorders and cardiometabolic side-effects: A comparison with prescription dose. — Liu Y, Sommer IE, Schoretsanitis G, Hamers I, Scheurink TAW, Begemann MJH et al. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology (2026)
[4]
How Does Altered Function of the Hippocampus Contribute to the Development of Psychosis? — Mancini V, Delavari F, Eom TY, Zakharenko SS, Schmitt E, Eliez S Biological psychiatry (2026)
[5]
Functional connectivity of the striatum in psychosis: Meta-analysis of functional magnetic resonance imaging studies and replication on an independent sample. — Grimaldi DA, Patane' A, Cattarinussi G, Sambataro F Neuroscience and biobehavioral reviews (2025)
[6]
Psychotic symptoms following consumption of energy drinks: a systematic review. — Wegmann Düring S, Botfeldt Møller-Pedersen T, Hovmand OR Nordic journal of psychiatry (2025)
[7]
Treatment approaches and efficacy in psychedelic-induced psychosis: A systematic review. — Sulstarova A, Scheuerlein L, Monari S, Seragnoli F, Gabriel T, Preller K et al. Asian journal of psychiatry (2025)
[8]
Over-the-counter Psychosis: A Systematic Review of the Misuse of Antihistamines, Cough Medicines, and Decongestants and the Risk of Developing Psychosis. — Mosca A, Chiappini S, Mancusi G, Miuli A, Marrangone C, Allegretti R et al. Current neuropharmacology (2025)
[9]
Letter from Lisbon. — Tavares de Almeida C The International journal of psycho-analysis (2025)
[10]
Navigating Uncertainty: Adapting Guidance for Mental Health During the COVID-19 Public Health Emergency & the Crucial Role of Bi-directional Feedback. — Montague E, Mendon-Plasek SJ, Stefancic A, Patel SR, Florence AC, Bello I et al. Administration and policy in mental health (2025)
[11]
Second-generation antipsychotic-induced dystonia: Analysis using the Japanese Adverse Drug Event Report (JADER) database. — Ebina T, Iwamoto K, Ando M, Ikeda M Psychiatry and clinical neurosciences (2025)
[12]
Sexual dysfunctions associated with antipsychotic drug intake: a retrospective analysis of the FDA adverse events reporting system (FAERS). — Engel J, Jeridi L, Auerbach L, Zolk O, Greiner T, Heinze M et al. Naunyn-Schmiedeberg's archives of pharmacology (2025)
[13]
Reporting Frequency of Antipsychotics-Induced Tardive Dyskinesia and Other Extrapyramidal Symptoms: Analysis Based on a Spontaneous Reporting System Database in Japan. — Saga Y, Horio H, Chiang CL, Wakamatsu A Neuropsychopharmacology reports (2025)
[14]
Signal mining and risk analysis of olanzapine adverse events in the FAERS database. — Dong A, Shi L, Du Z, Zhou Q, Jiang Y, Zhu H et al. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) (2025)
[15]
A real-world pharmacovigilance study of adverse events associated with esketamine: disproportionality analysis and detection of potential drug-drug interaction signals. — Pisanu C, Imai S, Tsuchiya M, Inoue M, Ikegami K, Zammarchi G et al. European journal of clinical pharmacology (2025)
[16]
Risk of corrected QT interval prolongation in patients receiving antipsychotics. — Rivas JC, Galindo-A J, Zambrano LF, Miranda-B CA, Ramírez SM, Rivas-Grajales AM et al. International clinical psychopharmacology (2025)
[17]
Unique Functional Neuroimaging Signatures of Genetic Versus Clinical High Risk for Psychosis. — Schleifer CH, Chang SE, Amir CM, O'Hora KP, Fung H, Kang JWD et al. Biological psychiatry (2025)
[18]
Cognitive Function and Variability in Antipsychotic Drug-Naive Patients With First-Episode Psychosis: A Systematic Review and Meta-Analysis. — Lee M, Cernvall M, Borg J, Plavén-Sigray P, Larsson C, Erhardt S et al. JAMA psychiatry (2024)
[19]
Comparative efficacy of akathisia treatments: A network meta-analysis. — Gambolò L, Bottignole D, D'Angelo M, Bellini L, Stirparo G CNS spectrums (2024)
[20]
The healing power of the doctor-patient relationship. — Karkal R Indian journal of medical ethics (2024)
[21]
Impact of long-acting injectable aripiprazole on the concomitant medication and antipsychotic polypharmacy: a retrospective, observational study of 127 patients with psychosis. — Lee J, Oh S, Moon SY, Loh SK, Kim M, Lee TY et al. International clinical psychopharmacology (2024)
[22]
Incorporating clinician insight and care plans into an audit and feedback initiative for antipsychotic prescribing to Medicaid-enrolled youth in Philadelphia. — Candon M, Shen S, Rothbard A, Reed A, Everett M, Demp N et al. BMC health services research (2024)
[23]
Clinical effects of CYP2D6 phenoconversion in patients with psychosis. — De Brabander EY, Breddels E, van Amelsvoort T, van Westrhenen R Journal of psychopharmacology (Oxford, England) (2024)
[24]
Discovering interactions in polypharmacy: Impact of metamizole on the metabolism of quetiapine. — Watermeyer F, Gaebler AJ, Neuner I, Haen E, Hiemke C, Schoretsanitis G et al. British journal of clinical pharmacology (2024)
[25]
A disproportionality analysis of antipsychotic-induced hyperprolactinemia based on FDA adverse event reporting system. — Song M, Li D, Peng J, Wang N, Zhang M, Ren XL International journal of clinical pharmacology and therapeutics (2024)
[26]
Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System. — Fusaroli M, Polizzi S, Menestrina L, Giunchi V, Pellegrini L, Raschi E et al. Drug safety (2024)
[27]
Withdrawal syndrome after antipsychotics discontinuation: an analysis of the WHO database of spontaneous reports (Vigibase) between 2000 and 2022. — Storck W, de Laportalière TT, Yrondi A, Javelot H, Berna F, Montastruc F Psychopharmacology (2024)
[28]
Weight gain, gender, and antipsychotics: a disproportionality analysis of the FDA Adverse Event Reporting System database (FAERS). — Stamoula E, Stamatellos VP, Vavilis T, Dardalas I, Papazisis G Expert opinion on drug safety (2024)
[29]
qEEG in the Diagnosis and Prognosis of a Case with Delusional Infestation. — Arıkan MK, İlhan R, Ozulucan MT, Aşık M Clinical EEG and neuroscience (2024)
[30]
Informing the development of a decision aid: Expectations and wishes from service users and psychiatrists towards a decision aid for antipsychotics in the inpatient setting. — Müller K, Schuster F, Krumm S, Leucht S, Siafis S, Heres S et al. Health expectations : an international journal of public participation in health care and health policy (2023)
[31]
Cariprazine for treating psychosis: an updated meta-analysis. — Generoso MB, Taiar I, Cordeiro Q, Shiozawa P, Kasper S International journal of psychiatry in clinical practice (2023)
[32]
Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and Recommendations. — Martino D, Karnik V, Bhidayasiri R, Hall DA, Hauser RA, Macerollo A et al. Movement disorders : official journal of the Movement Disorder Society (2023)
[33]
Psilocybin's Erasure of EGO. — Ahlskog G Psychoanalytic review (2023)
[34]
Weight Gain During Antipsychotic Treatment in Children, Adolescents, and Adults: A Disproportionality Analysis in the Global Pharmacovigilance Database, Vigibase — Kaguelidou F, Valtuille Z, Durrieu G, Delorme R, Peyre H, Treluyer JM et al. Drug safety (2023)
[35]
Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study. — Rogdaki M, Devroye C, Ciampoli M, Veronese M, Ashok AH, McCutcheon RA et al. Molecular psychiatry (2023)
[36]
Hypertension and psychosis. — Sudarshan Y, Cheung BMY Postgraduate medical journal (2023)
[37]
Periodontal disease in people with a history of psychosis: Results from the UK biobank population-based study. — Kang J, Palmier-Claus J, Wu J, Shiers D, Larvin H, Doran T et al. Community dentistry and oral epidemiology (2023)
[38]
Francis Pasche. — Bertrand M The International journal of psycho-analysis (2022)
[39]
The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation? — Lippi M, Fanelli G, Fabbri C, De Ronchi D, Serretti A International clinical psychopharmacology (2022)
[40]
Sexual dysfunction in people treated with long-acting injectable antipsychotics in monotherapy or polypharmacy: a naturalistic study. — Martínez-Giner G, Giménez-De Llano E, Romero-Rubio D, Abad-Pérez MJ, Sánchez-Martínez V International journal of mental health nursing (2022)
[41]
Understanding Identity Changes in Psychosis: A Systematic Review and Narrative Synthesis. — Conneely M, McNamee P, Gupta V, Richardson J, Priebe S, Jones JM et al. Schizophrenia bulletin (2021)
[42]
Second-Generation Antipsychotic Use in Pediatric Emergency Medicine. — Lambert C, Panagiotopoulos C, Davidson J, Goldman RD Pediatric emergency care (2021)
[43]
The Additional Effect of Individualized Prescriber-Focused Feedback on General Guideline Instruction in Reducing Antipsychotic Polypharmacy in Inpatients. — Lochmann van Bennekom MWH, Gijsman HJ, Groenewoud H, Verkes RJ Journal of clinical psychopharmacology (2021)
[44]
Antipsychotic use and Risk of Venous Thromboembolism: A Meta-Analysis. — Di X, Chen M, Shen S, Cui X Psychiatry research (2021)
[45]
Risk of Extrapyramidal Syndromes Associated With Psychotropic Polypharmacy: A Study Based on Large-Scale Japanese Claims Data. — Hirano Y Therapeutic innovation & regulatory science (2020)
[46]
Safety of clozapine use during pregnancy: Analysis of international pharmacovigilance data. — Beex-Oosterhuis MM, Samb A, Heerdink ER, Souverein PC, Van Gool AR, Meyboom RHB et al. Pharmacoepidemiology and drug safety (2020)
[47]
Keeping the body in mind: A qualitative analysis of the experiences of people experiencing first-episode psychosis participating in a lifestyle intervention programme. — Watkins A, Denney-Wilson E, Curtis J, Teasdale S, Rosenbaum S, Ward PB et al. International journal of mental health nursing (2020)
[48]
Socioeconomic deprivation and blood lipids in first-episode psychosis patients with minimal antipsychotic exposure: Implications for cardiovascular risk. — Veru-Lesmes F, Rho A, Joober R, Iyer S, Malla A Schizophrenia research (2020)
[49]
Screening for obstructive sleep apnoea in an early psychosis cohort: a pilot study. — Lane AR, Myles H, Foley S, Siskind D Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists (2020)
[50]
Early Symptoms may Help Identify Patients at High Risk for Psychosis. — Rosenberg K The American journal of nursing (2019)
[51]
A Research Agenda for Assessment and Management of Psychosis in Emergency Department Patients. — Peltzer-Jones J, Nordstrom K, Currier G, Berlin JS, Singh C, Schneider S The western journal of emergency medicine (2019)
[52]
Psychosis or spiritual emergency? A Foucauldian discourse analysis of case reports of extreme mental states in the context of meditation. — Kaselionyte J, Gumley A Transcultural psychiatry (2019)
[53]
Converging through difference: A case of empathic incongruence in treatment of an elderly woman with psychosis. — Pinto KC, Pinto S Journal of aging studies (2019)
[54]
Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 7: Relative Receptor Binding Affinity as a Way of Understanding the Differential Pharmacology of Currently Available Antipsychotics. — Preskorn SH Journal of psychiatric practice (2019)
[55]
Multi-trajectories of antidepressant and antipsychotic use: a 11-year naturalistic study in a community-based sample. — Verdoux H, Pambrun E, Tournier M, Cortaredona S, Verger P Acta psychiatrica Scandinavica (2019)
[56]
Adverse reaction reports of neuroleptic malignant syndrome induced by atypical antipsychotic agents in the Japanese Adverse Drug Event Report (JADER) database. — Anzai T, Takahashi K, Watanabe M Psychiatry and clinical neurosciences (2019)
[57]
Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database. — Subeesh V, Maheswari E, Singh H, Beulah TE, Swaroop AM Current drug safety (2019)
[58]
Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models. — Pillinger T, D'Ambrosio E, McCutcheon R, Howes OD Molecular psychiatry (2019)
[59]
Antipsychotic prescribing patterns on admission to and at discharge from a tertiary care program for treatment-resistant psychosis. — Lee LHN, Procyshyn RM, White RF, Woodward TS, Honer WG, Barr AM PloS one (2018)
[60]
Antipsychotic polypharmacy in older Australians. — Kalisch Ellett LM, Pratt NL, Kerr M, Roughead EE International psychogeriatrics (2018)
[61]
Prevalence and correlates of antipsychotic polypharmacy in Hong Kong. — Lung SLM, Lee HME, Chen YHE, Chan KWS, Chang WC, Hui LMC Asian journal of psychiatry (2018)
[62]
Is There a Potential of Misuse for Quetiapine?: Literature Review and Analysis of the European Medicines Agency/European Medicines Agency Adverse Drug Reactions' Database. — Chiappini S, Schifano F Journal of clinical psychopharmacology (2018)
[63]
Dopamine in high-risk populations: A comparison of subjects with 22q11.2 deletion syndrome and subjects at ultra high-risk for psychosis. — Vingerhoets C, Bloemen OJN, Boot E, Bakker G, de Koning MB, da Silva Alves F et al. Psychiatry research. Neuroimaging (2018)
[64]
Cortical Dysconnectivity Measured by Structural Covariance Is Associated With the Presence of Psychotic Symptoms in 22q11.2 Deletion Syndrome. — Sandini C, Scariati E, Padula MC, Schneider M, Schaer M, Van De Ville D et al. Biological psychiatry. Cognitive neuroscience and neuroimaging (2018)
[65]
Diet and cardiometabolic side effects in children treated with second-generation antipsychotics. — Barker MK, Sable CM, Montgomery SE, Chow L, Green TJ, Panagiotopoulos C et al. Clinical nutrition ESPEN (2018)
[66]
Total and differential white blood cell counts and hemodynamic parameters in first-episode psychosis. — Moody G, Miller BJ Psychiatry research (2018)
[67]
Chilling effect of 'ice' on emergency care provision. — Dixon M Emergency nurse : the journal of the RCN Accident and Emergency Nursing Association (2017)
[68]
Acute psychotic episode secondary to Helicobacter pylori eradication treatment. — Fernández Martos R, Burgos García A, Froilán Torres C Revista espanola de enfermedades digestivas (2017)
[69]
Letter to Editor. In search of definition of the term "psychotic process" - thoughts and doubts. — Kowalski J, Szaulińska K, Jarema M Psychiatria polska (2017)
[70]
Evaluation of Concurrent Oral and Long-Acting Injectable Antipsychotic Prescribing at the Minneapolis Veterans Affairs Health Care System. — Dimitropoulos E, Drogemuller L, Wong K Journal of clinical psychopharmacology (2017)
[71]
Cortical-amygdala volumetric ratios predict onset of symptoms of psychosis in 22q11.2 deletion syndrome. — Berhanu D, Mattiaccio LM, Antshel KM, Fremont W, Middleton FA, Kates WR Psychiatry research. Neuroimaging (2017)
[72]
The role of arterial elasticity and cardiovascular peripheral resistance as clinically relevant indices of health status in people with psychosis. — Hahn LA, Mackinnon A, Foley DL, Morgan VA, Waterreus A, Watts GF et al. Schizophrenia research (2017)
[73]
Antipsychotic drug exposure and risk of myocardial infarction. — Barbui C, Gastaldon C, Papola D, Ostuzzi G Epidemiology and psychiatric sciences (2017)
[74]
The Psychosis Spectrum in 22q11.2 Deletion Syndrome Is Comparable to That of Nondeleted Youths. — Tang SX, Moore TM, Calkins ME, Yi JJ, Savitt A, Kohler CG et al. Biological psychiatry (2017)
[75]
Longitudinal trajectories of cortical thickness as a biomarker for psychosis in individuals with 22q11.2 deletion syndrome. — Ramanathan S, Mattiaccio LM, Coman IL, Botti JC, Fremont W, Faraone SV et al. Schizophrenia research (2017)
[76]
Delusional infestation: a case series from a university dermatology center in São Paulo, Brazil. — Martins AC, Mendes CP, Nico MM International journal of dermatology (2016)
[77]
Acute laryngeal dystonia: a persisting psychiatric emergency. — May R, Al-Taie A, Garg V Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists (2016)
[78]
A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project. — Bioque M, Llerena A, Cabrera B, Mezquida G, Lobo A, González-Pinto A et al. The international journal of neuropsychopharmacology (2016)
[79]
Incident users of antipsychotics: who are they and how do they fare? — Baandrup L, Kruse M Social psychiatry and psychiatric epidemiology (2016)
[80]
Indicated prevention with long-chain polyunsaturated omega-3 fatty acids in patients with 22q11DS genetically at high risk for psychosis. Protocol of a randomized, double-blind, placebo-controlled treatment trial. — Armando M, De Crescenzo F, Vicari S, Digilio MC, Pontillo M, Papaleo F et al. Early intervention in psychiatry (2016)
[81]
Sudden cardiac and sudden unexpected death related to antipsychotics: A meta-analysis of observational studies. — Salvo F, Pariente A, Shakir S, Robinson P, Arnaud M, Thomas S et al. Clinical pharmacology and therapeutics (2016)
[82]
Hearing voices. Nursing standard (Royal College of Nursing (Great Britain) : 1987) (2015)
[83]
Antipsychotic Polypharmacy and Corrected QT Interval: A Systematic Review. — Takeuchi H, Suzuki T, Remington G, Uchida H Canadian journal of psychiatry. Revue canadienne de psychiatrie (2015)
[84]
Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials. — Jensen KG, Juul K, Fink-Jensen A, Correll CU, Pagsberg AK Journal of the American Academy of Child and Adolescent Psychiatry (2015)
[85]
Metoprolol and diltiazem ameliorate ziprasidone-induced prolonged corrected QT interval in rats. — Erbas O, Yilmaz M Toxicology and industrial health (2015)
[86]
Aripiprazole combined with other psychotropic drugs in pregnancy: two case reports. — Pirec V, Mehta A, Shoush S The Israel journal of psychiatry and related sciences (2014)
[87]
Atypical antipsychotic usage among Asian Americans and Pacific Islanders. — Takeshita J, Goebert D, Else I, Carlton B, Matsu C, Guerrero A Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health (2014)
[88]
Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. — Morrissette DA, Stahl SM CNS spectrums (2014)
[89]
Evidence for a crucial modulating role of the sodium channel in the QTc prolongation related to antipsychotics. — Silvestre JS, O'Neill MF, Prous JR Journal of psychopharmacology (Oxford, England) (2014)
[90]
Psychosis prevalence and physical, metabolic and cognitive co-morbidity: data from the second Australian national survey of psychosis. — Morgan VA, McGrath JJ, Jablensky A, Badcock JC, Waterreus A, Bush R et al. Psychological medicine (2014)
[91]
Adverse effects associated with high-dose olanzapine therapy in patients admitted to inpatient psychiatric care. — Petersen AB, Andersen SE, Christensen M, Larsen HL Clinical toxicology (Philadelphia, Pa.) (2014)
[92]
Psychopharmacologic treatment of psychosis in children and adolescents: efficacy and management. — Kranzler HN, Cohen SD Child and adolescent psychiatric clinics of North America (2013)
[93]
Antipsychotic polypharmacy prescribing patterns and costs in the Florida adult and child Medicaid populations. — Becker ER, Constantine RJ, McPherson MA, Jones ME Journal of health care finance (2013)
[94]
Multi-country rapid adverse drug event assessment: the Asian Pharmacoepidemiology Network (AsPEN) antipsychotic and acute hyperglycaemia study. — Pratt N, Andersen M, Bergman U, Choi NK, Gerhard T, Huang C et al. Pharmacoepidemiology and drug safety (2013)
[95]
Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database. — Poluzzi E, Raschi E, Koci A, Moretti U, Spina E, Behr ER et al. Drug safety (2013)
[96]
Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance. — Brunner E, Falk DM, Jones M, Dey DK, Shatapathy CC BMC pharmacology & toxicology (2013)
[97]
Adverse events in elderly users of antipsychotic pharmacotherapy in the province of Manitoba: a retrospective cohort study. — Vasilyeva I, Biscontri RG, Enns MW, Metge CJ, Alessi-Severini S Journal of clinical psychopharmacology (2013)
[98]
Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. — Raschi E, Poluzzi E, Godman B, Koci A, Moretti U, Kalaba M et al. PloS one (2013)
[99]
Psychiatric remission with warfarin: Should psychosis be addressed as plasminogen activator imbalance? — Hoirisch-Clapauch S, Nardi AE Medical hypotheses (2013)
[100]
First presentation psychosis among the elderly in Singapore. — Tan LL, Seng KH Singapore medical journal (2012)

Share:Twitter Reddit LinkedIn